logo BDSP

Base documentaire


  1. Modeled estimates of myocardial infarction and venous thromboembolic disease in users of second and third generation oral contraceptives.

    Article - En anglais

    Consistent reports from several recent studies suggest that users of third generation oral contraceptives (OCs) containing gestodene and desogestrel may be at increased risk of venous thromboembolic disease (VTE).

    Paradoxically, other reports indicate that these users may be at decreased risk of acute myocardial infarction (MI) compared with users of second generation OCs.

    To determine whether the potentially increased risk of VTE would outweigh the potentially reduced risk of MI in users of third generation OCs, we conducted an analysis to quantify the trade-offs providers and users may be faced to make between these formulations.

    The baseline rates of VTE and MI among non-users were calculated using US data on incidence and mortality of these conditions and estimates of the proportion of women exposed to these formulations in the US.

    These were multiplied by relative risks published in recent studies on third generation progestins to produce age-and formulation-specific risks.

    Results indicate that there would be small differences in disease burden between users of second and third generation OCs under the model assumptions at younger ages.

    However, among women 35-44 years of age, modeling results indicate that the potentially decreased incidence of MI among users of third generation OCs more than offsets the potentially increased risk of VTE at this age.

    Mots-clés Pascal : Contraceptif, Voie orale, Oestroprogestatif, Thromboembolie, Infarctus, Myocarde, Toxicité, Risque, Homme, Femelle, Epidémiologie, Mortalité, Morbidité, Progestatif, Gestodène, Désogestrel, Appareil circulatoire pathologie, Vaisseau sanguin pathologie, Cardiopathie coronaire, Myocarde pathologie, Age, Etats Unis, Amérique du Nord, Amérique, Progestatif troisième génération

    Mots-clés Pascal anglais : Contraceptive, Oral administration, Estroprogestagen, Thromboembolism, Infarct, Myocardium, Toxicity, Risk, Human, Female, Epidemiology, Mortality, Morbidity, Progestagen, Gestodene, Desogestrel, Cardiovascular disease, Vascular disease, Coronary heart disease, Myocardial disease, Age, United States, North America, America

    Logo du centre Notice produite par :
    Inist-CNRS - Institut de l'Information Scientifique et Technique

    Cote : 97-0272292

    Code Inist : 002B02U03. Création : 15/07/1997.



Fermeture du portail BDSP le 1er juillet 2019

Madame, Monsieur, utilisateurs du site BDSP et de ses services,

Nous avons le regret de vous informer de la fermeture du portail BDSP le 1er juillet 2019.

Pendant une période de transition de six mois, du 1er janvier au 30 juin 2019, le site et ses services resteront accessibles mais ne seront plus alimentés, ni mis à jour.

Plus précisément, concernant le service "Offres d'emploi", les dernières annonces seront publiées le 18 décembre 2018.

Concernant le service "Annonces de colloques", les dernières annonces seront publiées le 30 novembre 2018.

Nous vous informerons régulièrement sur le devenir des services (archivage ouvert, reprise, arrêt) et nous vous proposerons des réorientations vers des services similaires.

Continuez sur le site en cliquant ICI.

L'équipe de coordination de la BDSP